AU2021380836A1 - Use of short chain fatty acids in cancer prevention - Google Patents

Use of short chain fatty acids in cancer prevention Download PDF

Info

Publication number
AU2021380836A1
AU2021380836A1 AU2021380836A AU2021380836A AU2021380836A1 AU 2021380836 A1 AU2021380836 A1 AU 2021380836A1 AU 2021380836 A AU2021380836 A AU 2021380836A AU 2021380836 A AU2021380836 A AU 2021380836A AU 2021380836 A1 AU2021380836 A1 AU 2021380836A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
pharmaceutically
acceptable salt
compound
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021380836A
Other languages
English (en)
Inventor
Alla ARZUMANYAN
Mark A. Feitelson
Ira Spector
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
SFA Therapeutics Inc
Original Assignee
Sfa Therapeutics Inc
Temple Univ School of Medicine
SFA Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sfa Therapeutics Inc, Temple Univ School of Medicine, SFA Therapeutics Inc filed Critical Sfa Therapeutics Inc
Publication of AU2021380836A1 publication Critical patent/AU2021380836A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021380836A 2020-11-12 2021-11-12 Use of short chain fatty acids in cancer prevention Pending AU2021380836A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112783P 2020-11-12 2020-11-12
US63/112,783 2020-11-12
PCT/US2021/059211 WO2022104116A1 (en) 2020-11-12 2021-11-12 Use of short chain fatty acids in cancer prevention

Publications (1)

Publication Number Publication Date
AU2021380836A1 true AU2021380836A1 (en) 2023-06-22

Family

ID=81601740

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021380836A Pending AU2021380836A1 (en) 2020-11-12 2021-11-12 Use of short chain fatty acids in cancer prevention

Country Status (8)

Country Link
US (1) US20240009155A1 (enExample)
EP (1) EP4243803A4 (enExample)
JP (1) JP2023549522A (enExample)
KR (1) KR20230127990A (enExample)
CN (1) CN116782949A (enExample)
AU (1) AU2021380836A1 (enExample)
CA (1) CA3198162A1 (enExample)
WO (1) WO2022104116A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137671A1 (en) 2023-12-22 2025-06-26 Temple University-Of The Commonwealth System Of Higher Education Short chain fatty acid compounds and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030020482A (ko) * 2001-08-29 2003-03-10 대한민국(서울대학교) 소디움부티레이트를 유효성분으로 하는 항암제
US20100216754A1 (en) * 2007-11-13 2010-08-26 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
KR102735818B1 (ko) * 2015-01-23 2024-11-28 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 암 예방에서 단쇄 지방산의 용도
WO2018089861A1 (en) * 2016-11-11 2018-05-17 The Regents Of The University Of California Methods and compositions for the treatment of cancer and metabolic diseases
WO2018140687A1 (en) * 2017-01-27 2018-08-02 Temple University-Of The Commonwealth System Of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
AU2019358875B2 (en) * 2018-10-09 2025-08-21 Monash University Combination therapy for treatment and prevention of autoimmune and inflammatory diseases

Also Published As

Publication number Publication date
WO2022104116A1 (en) 2022-05-19
EP4243803A1 (en) 2023-09-20
EP4243803A4 (en) 2024-10-23
KR20230127990A (ko) 2023-09-01
JP2023549522A (ja) 2023-11-27
US20240009155A1 (en) 2024-01-11
CA3198162A1 (en) 2022-05-19
CN116782949A (zh) 2023-09-19

Similar Documents

Publication Publication Date Title
Mohamed et al. Coenzyme Q10 attenuates inflammation and fibrosis implicated in radiation enteropathy through suppression of NF-kB/TGF-β/MMP-9 pathways
Tozaki et al. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
JP7161731B2 (ja) 疾患及び障害の処置及び予防のための短鎖脂肪酸の使用
PT1663194E (pt) Utilizaã†o de saha para o tratamento de mesotelioma
JP2011509253A (ja) 抗菌ペプチド系に対する作動薬
WO2005082349A1 (en) Composition for the treatment of obesity comprising fumagillol derivative
RU2753523C2 (ru) УЛУЧШЕННЫЙ ТЕРАПЕВТИЧЕСКИЙ ИНДЕКС ИНГИБИТОРОВ ПРОТИВ ИММУННОЙ КОНТРОЛЬНОЙ ТОЧКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ, ВКЛЮЧАЮЩЕЙ ЭКСТРАКТ PHY906, ЭКСТРАКТ Scutellaria baicalensis Georgi (S) ИЛИ СОЕДИНЕНИЕ ИЗ ТАКИХ ЭКСТРАКТОВ
Sheng et al. A nucleotide analog prevents colitis-associated cancer via beta-catenin independently of inflammation and autophagy
US20240382512A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
CN113908159A (zh) 西奥罗尼及其联合用药治疗非霍奇金淋巴瘤的用途
US20240009155A1 (en) Use of short chain fatty acids in cancer prevention
WO2015015039A9 (es) Potenciación del efecto del metotrexato mediante el uso combinado con estatinas lipofílicas
US11684601B2 (en) Treatment of cancer with combinations of agents
JP2024511836A (ja) 膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤
CA3145824A1 (en) System for enhancing therapeutic compliance of the anti-cancer compound e7766
CN116850289A (zh) Plk4靶向药物在治疗对铂类药物耐药型肿瘤中的应用
US6800446B2 (en) Therapeutic and diagnostic methods for ulcerative colitis and associated disorders
US20230064307A1 (en) Pharmaceutical composition to destabilize abnormal methylation enzymes and use thereof
US20060100286A1 (en) Treatment of canine hemangiosarcoma with a histone deacetylase inhibitor
Kusmardi et al. Research Article Ethanol Extract of Pomegranate (Punica granatum) Peel in Increasing the Expression of Caspase-3 in DSS-Induced Mice
Yu et al. Deficiency of osteopontin in gut epithelial cells enhances intestinal integrity by promoting gut renewal through the JAK3/STAT4 pathway in acetaminophen (APAP)-induced acute liver injury
JP2026500734A (ja) 医薬組み合わせ、及びその使用
AU2023337869A1 (en) Compositions and methods for amelioration of symptoms associated with clec16a dysfunction or loss
CN117224557A (zh) 柚皮苷联合雷帕霉素在制备治疗高脂血症的药物中的应用